妇科恶性肿瘤多学科诊疗中国专家共识（2022年版）发表时间：2022-10-09 13:24 引用本文 ［摘要］近年来，随着妇科恶性肿瘤综合治疗新策略的不断涌现，以及生殖肿瘤学和遗传肿瘤理念的演进，传统的“单学科诊疗”模式已难于以最优的方案解决患者的诊疗问题。多学科诊疗（multidisciplinary team，MDT）可以使患者获得最科学、最合理的诊疗，有利于改进和完善现有的治疗方式，从而提高医疗效率及质量。基于MDT领域国内外最新研究进展及临床实践经验，中国抗癌协会妇科肿瘤专业委员会组织国内妇科肿瘤及相关领域的专家，针对妇科恶性肿瘤MDT运行流程、监测评估及质量控制机制，制订了《妇科恶性肿瘤多学科诊疗中国专家共识（2022年版）》，希望通过本共识，提高中国临床工作者对于妇科恶性肿瘤MDT的认识，以指导和规范MDT在妇科恶性肿瘤中的临床运用。 ［关键词］ 妇科；肿瘤；多学科综合治疗；共识 ［Abstract］ Recently, new strategies for gynecological malignancies integrated treatments have been improved along with the development of reproductive oncology and hereditary tumors, the traditional “single-disciplinary treatment” mode is difficult to solve the diagnosis and treatment problems of patients in optimal decision. The application of multidisciplinary team (MDT) can provide the most scientific and reasonable diagnosis and treatment plan for patients, as well as to refine the existing therapies and improve the efficacy of quality of medical treatment. Based on the most recent advances and clinical practice experience in MDT of gynecological malignancies, The Society of Gynecological Cancer of China Anti-Cancer Association have organized multidisciplinary experts in gynecologic oncology and related area to formulate “Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition)”, in order to improve the understanding of MDT among Chinese gynecologic oncologists, and further standardize the application of MDT in gynecological malignancies. ［Key words］ Gynecology; Tumor; Multidisciplinary team; Consensus 1 MDT的目的、责任和义务 1.1 主要目的［16-20］ 1.2 责任和义务［16，21-22］ 2 MDT制度管理 2.1 行政和临床共同管理 2.2 MDT的运行制度 2.3 MDT运行中的质量管理 3 MDT团队的组织建设［19，23］ 3.1 MDT组织构架 3.2 MDT团队成员基本要求［16，24］ 3.3 MDT团队的成员职责［4，18，25-30］ 3.4 基础设施的配置 4 MDT的组织及实施 4.1 MDT会议时间安排及患者纳入标准 4.2 MDT的标准化流程（图1、2）［30，32］   ⑷ 决策方案的制订［29］：综合MDT的共识意见，由MDT首席专家最终确定合理的个体化治疗方案，并交由相关专科具体实施。临床决策制定需符合如下标准：① 方案的制订需有证据支持， 具体可参考国内外权威机构制订的指南与共识；② 通常需选择标准诊治方案，在特殊情况下，因诊疗条件的限制，需有足够理由选择其他非标准治疗方案作为替代，并应将实际情况记录在案。③ 建议推荐两种及以上的治疗方案或可替代方案供患者及家属选择，充分告知每个方案的优劣，尊重患者的知情同意权，取得明确的知情同意并签字后方可执行。④ 了解所有当前正在进行的临床试验，评估患者能否参与临床试验，作为临床决策的一部分，必要时可请相关临床试验的协作者或研究者参加MDT会议。 5 MDT监测评估及质量控制指标 5.1 肿瘤诊疗规范性指标 5.2 MDT运行情况指标 5.3 MDT病例疗效指标 5.4 卫生经济学指标   ［1］SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209-249. ［2］ LAMB B W, SEVDALIS N, TAYLOR C, et al. Multidisciplinary team working across different tumour types: analysis of a national survey［J］. Ann Oncol, 2012, 23(5): 1293-1300. ［3］TABERNA M, GIL MONCAYO F, JANÉ-SALAS E, et al. The multidisciplinary team (MDT) approach and quality of care［J］. Front Oncol, 2020, 10: 85. ［4］FALZONE L, SCANDURRA G, LOMBARDO V, et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review)［J］. Int J Oncol, 2021, 59(1): 53. ［5］ BAERT T, FERRERO A, SEHOULI J, et al. The systemic treatment of recurrent ovarian cancer revisited［J］. Ann Oncol, 2021, 32(6): 710-725. ［6］ TAYLOR C, SHEWBRIDGE A, HARRIS J, et al. Benefits of multidisciplinary teamwork in the management of breast cancer［J］. Breast Cancer (Dove Med Press), 2013, 5: 79-85. ［7］ LICITRA L, KEILHOLZ U, TAHARA M, et al. Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer［J］. Oral Oncol, 2016, 59: 73-79. ［8］ ELNAHAL S M, PRONOVOST P J, HERMAN J M. More than the sum of its parts: how multidisciplinary cancer care can benefit patients, providers, and health systems［J］. J Natl Compr Canc Netw, 2013, 11(6): 738-742. ［9］ HUNG H Y, TSENG Y H, CHAO H S, et al. Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer［J］. PLoS One, 2020, 15(10): e0236503. ［10］ KHALAFALLAH A M, JIMENEZ A E, ROMO C G, et al. Quantifying the utility of a multidisciplinary neuro-oncology tumor board［J］. J Neurosurg, 2020: 1-6. ［11］PRABHAKAR C N, FONG K M, PEAKE M D, et al. The effectiveness of lung cancer MDT and the role of respiratory physicians［J］. Respirology, 2015, 20(6): 884-888. ［12］HAWARD R A. The Calman-Hine report: a personal retrospective on the UK’s first comprehensive policy on cancer services［J］. Lancet Oncol, 2006, 7(4): 336-346. ［13］JUNOR E J, HOLE D J, GILLIS C R. Management of ovarian cancer: referral to a multidisciplinary team matters［J］. Br J Cancer, 1994, 70(2): 363-370. ［14］COHEN P, TAN A L, PENMAN A. The multidisciplinary tumor conference in gynecologic oncology: does it alter management?［J］. Int J Gynecol Cancer, 2009, 19(9): 1470-1472. ［15］CARLSON J W, STOJADINOVIC A, ENNIS W, et al. Multidisciplinary panel discussion of a gynecologic oncology patient: preventing wound complications［J］. Gynecol Oncol, 2008, 111(2 Suppl): S98-S100. ［16］PILLAY B, WOOTTEN A C, CROWE H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature［J］. Cancer Treat Rev, 2016, 42: 56-72. ［17］ALETTI G D, GARBI A, MESSORI P, et al. Multidisciplinary approach in the management of advanced ovarian cancer patients: a personalized approach. Results from a specialized ovarian cancer unit［J］. Gynecol Oncol, 2017, 144(3): 468-473. ［18］SCOTT R, HAWARDEN A, RUSSELL B, et al. Decision-making in gynaecological oncology multidisciplinary team meetings: a cross-sectional, observational study of ovarian cancer cases［J］. Oncol Res Treat, 2020, 43(3): 70-77. ［19］SELBY P, POPESCU R, LAWLER M, et al. The value and future developments of multidisciplinary team cancer care［J］. Am Soc Clin Oncol Educ Book, 2019, 39: 332-340. ［20］SPECCHIA M L, FRISICALE E M, CARINI E, et al. The impact of tumor board on cancer care: evidence from an umbrella review［J］. BMC Health Serv Res, 2020, 20(1): 73. ［21］FUNG-KEE-FUNG M, KENNEDY E B, BIAGI J, et al. An organizational guideline for gynecologic oncology services［J］. Int J Gynecol Cancer, 2015, 25(4): 551-558. ［22］RAUSEI S, UCCELLA S, D’ALESSANDRO V, et al. Aggressive surgery for advanced ovarian cancer performed by a multidisciplinary team: a retrospective analysis on a large series of patients［J］. Surg Open Sci, 2019, 1(1): 43-47. ［23］EL SAGHIR N S, CHARARA R N, KREIDIEH F Y, et al. Global practice and efficiency of multidisciplinary tumor boards: results of an American society of clinical oncology international survey［J］. J Glob Oncol, 2015, 1(2): 57-64. ［24］中国医师协会神经外科医师分会脑胶质瘤专业委员会. 胶质瘤多学科诊治(MDT)中国专家共识［J］. 中华神经外科杂志, 2018, 34(2): 113-118. Professional Committee of Brain Glioma, Branch of Neurosurgeons, Chinese Medical Doctor Association. Consensus of Chinese experts on multidisciplinary team (MDT) of brain glioma［J］. Chin J Neurosurg, 2018, 34(2): 113-118. ［25］JALIL R, LAMB B, RUSS S, et al. The cancer multi-disciplinary team from the coordinators’ perspective: results from a national survey in the UK［J］. BMC Health Serv Res, 2012, 12: 457. ［26］OSAROGIAGBON R U, FREEMAN R K, KRASNA M J. Implementing effective and sustainable multidisciplinary clinical thoracic oncology programs［J］. Transl Lung Cancer Res, 2015, 4(4): 448-455. ［27］张建栋, 李梁和, 陈忠胜, 等. 多学科团队协作在中晚期结直肠癌诊疗价值的研究［J］. 贵州医药, 2021, 45(3): 355-358. ZHANG J D, LI L H, CHEN Z S, et al. Study on the value of multidisciplinary teamwork in the diagnosis and treatment of advanced colorectal cancer［J］. Guizhou Med J, 2021, 45(3): 355-358. ［28］中国医师协会妇产科医师分会妇科肿瘤学组. 卵巢恶性肿瘤多学科团队协作诊治的中国专家共识［J］. 中华妇产科杂志, 2021, 56(12): 825-830. Gynecological Oncology Group, Branch of Obstetricians and Gynecologists, Chinese Medical Doctor Association. Chinese consensus on multi-disciplinary team treatment of ovarian malignancies［J］. Chin J Obstet Gynecol, 2021, 56(12): 825-830. ［29］钟文昭, 中国胸部肿瘤研究协作组, 中国抗癌协会肺癌专业委员会, 等. 肺癌多学科团队诊疗中国专家共识［J］. 中华肿瘤杂志, 2020, 42(10): 817-828. ZHONG W Z, China Thoracic Cancer Research Collaborative Group, Lung Cancer Committee of Chinese Anti-Cancer Association, et al. Chinses expert consensus on the multidisciplinary team diagnosis and treatment of lung cancer［J］. Chin J Oncol, 2020, 42(10): 817-828. ［30］叶定伟, 秦晓健, 朱 耀, 等. 泌尿男生殖系统肿瘤多学科团队诊治组织与实施规范中国专家共识（2020年版）［J］.中国癌症杂志, 2020, 30(4): 313-320. YE D W, QIN X J, ZHU Y, et al. Consensus of Chinese experts on the organization and implementation of the multidisciplinary team for diagnosis and treatment of genitourinary system tumors (2020 edition)［J］. China Oncol, 2020, 30(4): 313-320. ［31］HEUDEL P E, DEVOUASSOUX-SHISHEBORAN M, TAIEB S, et al. Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy［J］. Eur J Gynaecol Oncol, 2017, 38(2): 175-180. ［32］王成锋, 杨尹默, 傅德良, 等. 中国胰腺癌多学科综合治疗模式专家共识（2020版）［J］. 临床肝胆病杂志, 2020, 36(9): 1947-1951. WANG C F, YANG Y M, FU D L, et al. Expert consensus on the MDT model of pancreatic cancer in China (2020 version)［J］. J Clin Hepatol, 2020, 36(9): 1947-1951. ［33］DE FELICE F, TOMBOLINI V, DE VINCENTIIS M, et al. Multidisciplinary team in head and neck cancer: a management model［J］. Med Oncol, 2018, 36(1): 2. ［34］QUARANTA M, NATH R, MEHRA G, et al. Surgery of benign ovarian masses by a gynecological cancer surgeon: a cohort study in a tertiary cancer centre［J］. Cureus, 2020, 12(7): e9201. ［35］TOOKMAN L, KRELL J, NKOLOBE B, et al. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting［J］. Ther Adv Med Oncol, 2020, 12: 1758835920921980. ［36］RASPOLLINI M R, LAX S F, MCCLUGGAGE W G. The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines［J］. Virchows Arch, 2018, 473(1): 45-54. ［37］KOH W J, ABU-RUSTUM N R, BEAN S, et al. Cervical cancer, version 3 2019, NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw, 2019, 17(1): 64-84. ［38］ MINIG L, PADILLA-ISERTE P, ZORRERO C. The relevance of gynecologic oncologists to provide high-quality of care to women with gynecological cancer［J］. Front Oncol, 2015, 5: 308. ［39］COLOMBO N, CREUTZBERG C, AMANT F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up［J］. Radiother Oncol, 2015, 117(3): 559-581. ［40］SPOOR E, CROSS P. Audit of endometrial cancer pathology for a regional gynecological oncology multidisciplinary meeting［J］. Int J Gynecol Pathol, 2019, 38(6): 514-519. ［41］TRIMBLE E L. The NIH consensus conference on ovarian cancer: screening, treatment, and follow-up［J］. Gynecol Oncol, 1994, 55(3 Pt 2): S1-S3. ［42］NEWTON C, NORDIN A, ROLLAND P, et al. British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)［J］. Int J Gynecol Cancer, 2020, 30(5): 695-700. 加入癌症早筛行业交流群，请关注早筛网公众号，后台回复 “进群”。 |
邮编：510000/430000